These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
563 related articles for article (PubMed ID: 17143602)
1. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602 [TBL] [Abstract][Full Text] [Related]
2. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988 [TBL] [Abstract][Full Text] [Related]
3. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932 [TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321 [TBL] [Abstract][Full Text] [Related]
5. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study. Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377 [TBL] [Abstract][Full Text] [Related]
6. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Park SH; Park YH; Lee JN; Bang SM; Cho EK; Shin DB; Lee JH Cancer; 2006 Jan; 106(2):361-5. PubMed ID: 16342166 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Li YH; Wang FH; Jiang WQ; Xiang XJ; Deng YM; Hu GQ; Xu DM; Chen Y; Lin Q; He YJ Cancer Chemother Pharmacol; 2008 Aug; 62(3):539-44. PubMed ID: 18172651 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer. Cho EK; Lee WK; Im SA; Lee SN; Park SH; Bang SM; Park DK; Park YH; Shin DB; Lee JH Oncology; 2005; 68(4-6):333-40. PubMed ID: 16020960 [TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy. Peng PJ; Ou XQ; Chen ZB; Liao H; Peng YL; Wang SY; Zhang HY; Lin Z Cancer Chemother Pharmacol; 2013 Aug; 72(2):323-8. PubMed ID: 23728706 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer. Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02. Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cantore M; Mambrini A; Fiorentini G; Rabbi C; Zamagni D; Caudana R; Pennucci C; Sanguinetti F; Lombardi M; Nicoli N Cancer; 2005 Apr; 103(7):1402-7. PubMed ID: 15726542 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. Lim JY; Jeung HC; Mun HS; Lee DK; Paik YH; Lee SJ; Yoon DS; Cho JY Anticancer Drugs; 2008 Jul; 19(6):631-5. PubMed ID: 18525323 [TBL] [Abstract][Full Text] [Related]
17. [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study]. Hu B; Yu JR; Wen ZZ; Shu YQ; Wang BC; Yin HR; Chen L; Bai YX; Liang J; Chen L; Cheng Y; Shen L; Zhou Y; Zhang HG; Li J; Wan DS; Chen S; Jia TZ; Jin ML Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):940-3. PubMed ID: 19173999 [TBL] [Abstract][Full Text] [Related]
18. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213 [TBL] [Abstract][Full Text] [Related]
19. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641 [TBL] [Abstract][Full Text] [Related]